HepaLife spinoff to bring wound-care products to market

11/1/2010 | MassDevice.com (Boston)

HepaLife Technologies has set up a unit, Alliqua BioMedical, that will focus on developing and commercializing transdermal drug-delivery systems and wound-care products using HepaLife's intellectual property. AquaMed Technologies CEO Matt Harriton has been appointed by HepaLife to serve as the spinoff's chief executive.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT